In patients with CD19+ B‐cell lymphoma or chronic lymphocytic leukemia, CAR‐NK cells engineered to express anti‐CD19 CAR, IL‐15, and an inducible caspase‐9 safety switch achieved a 64% complete response (CR) rate, with no major adverse events reported. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.